Related Experiment Video

Updated: May 25, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

Reinhard Dummer1, Keith T Flaherty

  • 1Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. reinhard.dummer@usz.ch

Current Opinion in Oncology
|February 10, 2012
PubMed
Abstract

Insights

New kinase inhibitors show promise for metastatic melanoma, improving survival. However, resistance limits their long-term antiproliferative effects, prompting research into new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Metastatic melanoma treatment historically faced limited therapeutic options.
  • Recent advancements include serine-threonine and tyrosine kinase inhibitors, offering improved clinical efficacy and patient survival.

Purpose of the Study:

  • To review the molecular basis for targeted kinase inhibitor development in melanoma.
  • To summarize the clinical impact of these inhibitors on advanced melanoma.
  • To explore emerging mechanisms of resistance to kinase inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of molecular pathways targeted by kinase inhibitors.
  • Synthesis of data on clinical trial outcomes and resistance patterns.

Main Results:

  • Kinase inhibitors have demonstrated significant early clinical efficacy in metastatic melanoma.
  • Improved survival rates have been observed in patients treated with these targeted therapies.
  • Limited antiproliferative effects and development of resistance are key challenges.

Conclusions:

  • While kinase inhibitors represent a breakthrough, their efficacy is constrained by resistance.
  • Understanding resistance mechanisms is crucial for developing next-generation melanoma therapies.
  • Future research should focus on identifying novel targets to overcome treatment limitations.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...